BioSpace News Archive

Genetown

Catabasis Pharmaceuticals Reports Edasalonexent Preserved Muscle Function and Substantially Slowed Duchenne Muscular Dystrophy Disease Progression Through More Than One Year of Treatment

Catabasis today reported new positive efficacy and safety results showing preservation of muscle function and sustained disease-modifying effects in boys with Duchene muscular dystrophy (DMD) in the MoveDMD trial open-label extension following 48 and 60 weeks of treatment with edasalonexent.

February 13, 2018

·

11 min read

Drug Development

Obsidian Therapeutics Presents Data Demonstrating Regulation of Protein Activity with its Next-Generation CAR-T Platform at Keystone Symposium on Emerging Cellular Therapies

Obsidian today announced the presentation of preclinical data on its technology platform and applications at the Keystone Symposium on Emerging Cellular Therapies, to be held February 11-15, 2018 in Keystone, Colorado.

February 13, 2018

·

3 min read

Genetown

Synlogic Presents Data from Immuno-Oncology Development Program Demonstrating Potent Anti-Tumor Immunity Following Administration of Novel STING Agonist-producing Synthetic Biotic Medicine

The meeting is being held jointly with a related session, Emerging Cellular Therapies T-cells and Beyond, from February 11 to 15, 2018.

February 13, 2018

·

6 min read

Policy

Advaxis Submits Conditional MAA for Axalimogene Filolisbac for the Second-Line Treatment of Metastatic Cervical Cancer in EU

The MAA submission is centered around the encouraging results from the GOG-0265 study.

February 13, 2018

·

6 min read

Counsyl Celebrates Anniversary With $80M F

BioMidwest

Colorado’s Viveve Closes $32.4M Offering

Viveve intends to use the cash for supporting the commercialization of its products, clinical research and development, working capital and general corporate purposes.

February 13, 2018

·

4 min read

Deals

Mallinckrodt Completes Acquisition of Sucampo

The tender offer by a subsidiary of Mallinckrodt for all of the outstanding shares of Sucampo Class A common stock expired as scheduled at 8:00 a.m. on February 13, 2018.

February 13, 2018

·

8 min read

Business

Cytobank and the FDA Collaborate to Improve Immunotherapy Development

Cytobank and the FDA are collaborating to develop machine learning-based methods for characterizing the morphology of multipotent mesenchymal stromal cells (MSCs).

February 13, 2018

·

2 min read

Drug Development

Arch Biopartners Announces AB569 Phase I Human Trial Begins Patient Recruitment and Enrollment Stage

AB569 is the Company’s inhalation drug candidate for treating antibiotic-resistant bacterial infections in the lungs of CF and COPD patients.

February 13, 2018

·

3 min read

Business

Executive Chairman of Anthem Inc., Joseph Swedish, Joins the Board of Proteus Digital Health

Proteus Digital Health announced today that Joseph Swedish, the Executive Chairman of Anthem Inc., has joined its Board of Directors.

February 13, 2018

·

3 min read

Policy

Abiomed Announces Peripartum and Postpartum Cardiomyopathy Approval and Women’s Initiative for Heart Recovery

This Women’s Initiative is in conjunction with the Company’s expanded FDA approval for cardiogenic shock associated with cardiomyopathy.

February 13, 2018

·

8 min read